Cancer and Heart Disease Prediction Technology by SugarStrings.ai

Shark Tank India recently showcased three visionary founders from Kerala and Andhra Pradesh who presented their groundbreaking invention capable of forecasting cancer and heart ailments. Dr. Rajasekhara Reddy Ravuri, Dhaneesh Jameson, and Tony Jose introduced their venture, SugarStrings.ai, which provides DNA-based health assessments. This genetic analysis, enhanced by machine learning, seeks to unveil diseases stemming from gene mutations. The team aimed for ₹1 crore in exchange for 2.5% equity, thereby valuing their company at ₹40 crore.

Claims of Enhanced Accuracy

The founders asserted that while other comparable products boast an accuracy of merely 40%, their solution is significantly more reliable. Nonetheless, certain exaggerated assertions were moderated during the televised segment. Regardless, the presentation left the investors in awe.

Predicting Health Risks

The team claimed their offering could pinpoint genetic indicators associated with cancer and heart conditions, potentially allowing for early predictions of these diseases. Azhar Iqubal, co-founder of Inshorts, appeared visibly astonished by these claims.

Sales Performance and Customer Insights

Having launched half a year ago, SugarStrings.ai sold only 32 units thus far. Out of these, four customers were indicated as having potential cancer risks, though the founders acknowledged that these predictions could only be verified if those individuals received a subsequent diagnosis. The test is priced at ₹58,000, and when questioned about the process, they clarified that customers are required to conduct the test themselves upon receiving it via courier. This revelation astonished Azhar, who contended that such a high-priced test should ideally be accompanied by professional guidance.

Concerns from the Sharks

Aman Gupta expressed reservations regarding accuracy, particularly in a nation where a substantial segment of the population lacks health insurance. He stated, “Samajh nahi aa raha ki yeh genuine hoga ya nahi hoga,” questioning the dependability of the forecasts. He also expressed concerns over the possibility of false positives, remarking, “Meri toh zindagi kharab ho jayegi.”

Proof of Effectiveness

Vineeta Singh highlighted that while the test may not be unaffordable for all, there was no substantial evidence to confirm its effectiveness. Ritesh Agarwal mirrored this apprehension, pointing out that the technology is still in its nascent phases within India. Azhar stressed that any significant medical innovation must be supported by solid research, yet the founders did not provide the necessary scientific validation.

Potential Yet Uncertain

Kunal Bahl acknowledged the promise of the concept but remained sceptical about its current readiness for market entry. Ultimately, none of the sharks extended an offer, resulting in the founders departing without securing a deal.